300396 Dirui Industrial
- 25.28
- -0.31-1.21%
Dirui Industrial News
Express News | Dirui Medical: Eleven medical device products have recently obtained IVDRCE certification.
Express News | Diray medical products obtained EU IVDR certification
Dirui Healthcare (300396.SZ) 2023 equity distribution: 5 yuan for every 10 shares Equity Registration Date May 20
Dirui Healthcare (300396.SZ) issued an announcement. The company's 2023 equity distribution plan is: With the company's current...
Dirui Healthcare (300396): Consolidate domestic business and accelerate expansion of overseas markets
Matters: The company publishes financial reports. The company's revenue in '23 was 1,378 million yuan (+12.96%), net profit attributable to mother was 276 million yuan (+5.26%), after deducting non-net profit of 262 million yuan (+5.36%). 2
Diri Healthcare (300396): The pace of delivery has led to quarterly fluctuations and rapid overseas growth
Guide to this report: The pace of delivery has led to quarterly fluctuations in 2023Q4 and 2024Q1 performance. Domestic market installed capacity is actively promoted. It is expected that reagent volumes will increase. Localization in the international market will continue to advance, and it is expected that rapid growth will continue. Maintain an increase in holdings rating.
Tianfeng Securities released a research report on April 23 stating that it gave Dirui Healthcare (300396.SZ) a purchase rating. The main reasons for the rating include: 1) strengthening channel empowerment, which is worth looking forward to; 2) continuing
Tianfeng Securities released a research report on April 23 stating that it gave Dirui Healthcare (300396.SZ) a purchase rating. The main reasons for the rating include: 1) strengthening channel empowerment, which is worth looking forward to; 2) continuing to increase overseas, major customer strategy+localization management upgrades drive high growth in the international market; 3) changes in product structure are expected to drive increased profitability. (Mainichi Keizai Shimbun)
Dirui Medical (300396): High performance in 2024Q1, the increase in reagent volume is worth looking forward to
Incident: On April 19, 2024, Diri Healthcare disclosed the 2023 Annual Report and 2024 Quarterly Report. In 2023, the company achieved revenue of 1,378 billion yuan, +12.96% over the same period last year; achieved return
Express News | Dirui Healthcare: Net profit of 122 million yuan in the first quarter of 2024 increased 56.73% year-on-year
Diri Healthcare (300396.SZ): Currently, revenue in the EU market accounts for a small proportion of the company's total revenue
Gelonghui, April 17 | Dirui Medical (300396.SZ) said on the investor interactive platform that the company's current revenue in the EU market accounts for a small proportion of the company's total revenue. According to rough statistics, it is less than 3%. The main products are mainly based on cost-effective urine. In response to related rumors, we communicated with local regional officials and verified with dealers who have been cooperating for many years. According to actual business feedback, the company's business is all normal and has not been affected in any way. Dirui Medical has been working in the international market for more than 20 years, and the company strictly complies with local laws and regulations to promote product sales.
Huade Xinrun, the controlling shareholder of Dirui Healthcare (300396.SZ), lifted the pledge of 45.6002 million shares
Dirui Medical (300396.SZ) announced that part of the company's shares held by Shenzhen Huade Xinrun Equity Investment Enterprise (Limited Partnership) (“Huade Xinrun”), the controlling shareholder of the company, was released. 45.602 million shares were released from the pledge this time, accounting for 16.61% of the company's total share capital.
Dirui Industrial Gets Nod to Register 19 Devices
Dirui Industrial (SHE:300396) received registration certificates for 19 medical devices, according to a Monday disclosure published on the Shenzhen Stock Exchange. The certificate was from the drug ad
Express News | Dirui Healthcare: The company's performance maintained a steady growth trend as of the end of February
Rui Healthcare (300760): Release of an action plan to double improve quality return, highlighting the value of leading medical devices
Core view The company issued the “Double Improvement of Quality and Return” action plan, which is expected to help the company achieve high-quality development. In the short term, the company is expected to continue to benefit from new domestic medical infrastructure and the continuous expansion of the overseas high-end customer base, and advance through the merger and acquisition of Huitai Healthcare
Dirui Healthcare (300396): Revitalizing, China Resources enters the market to enable high-quality development
As an established company that has been deeply involved in the field of in vitro diagnosis for many years, Dirui Medical's revenue rose from 176 million yuan to 906 million yuan between 2009 and 2021, maintaining steady growth. In 2022, thanks to China Resources entering the mainstream
Dirui Medical (300396) First Coverage Report: China Resources Empowers Collaborative Instruments to Strengthen Market Layout
Deeply involved in IVD for many years, China Resources has entered a new chapter. Dirui Medical was founded in 1992. It has been deeply involved in the in vitro diagnosis industry for more than 30 years, starting with urine analysis to enter the diagnostic equipment industry. In recent years, various product lines have continued to be introduced, with seven major business segments
SDIC Securities: Leading companies related to domestic IVD speeding up overseas development to build a second growth engine are expected to seize the opportunity
Going overseas is of great significance in increasing the development space of enterprises and extending the stage of rapid development of performance.
Diri Healthcare (300396): Alzheimer's Testing's New Patent Is Authorized to Enter the 10 Billion AD Testing Market
Incident: On January 11, 2024, the company announced that it has obtained a patent license for the “Alzheimer-related neurofilin chemiluminescence immunoassay kit and its preparation method”. Reviews: 1. Alzheimer's disease (AD) in our country
Dirui Healthcare (300396.SZ) has once again passed the certification of a high-tech enterprise
On November 24, Gelonghui Healthcare (300396.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Jilin Provincial Department of Science and Technology, the Jilin Provincial Department of Finance, and the Jilin Provincial Taxation Bureau of the State Administration of Taxation. The company once again successfully passed the certification of a high-tech enterprise.
The medical device sector fluctuated, and DiRi Medical surged 10%
Gelonghui, November 17 | The medical device sector fluctuated higher in the afternoon. Diri Healthcare surged 10%. Sano Healthcare, Xinhua Healthcare, Tailin Biotech, Microphysiology, Weiss Medical, etc. followed suit. According to the news, the State-organized Joint Procurement Office for High-Value Medical Consumables recently issued a notice that the fourth batch of state-organized high-value medical consumables collection will be opened on November 30, including artificial crystals and sports medicine consumables products.
Review of the '23 Three Quarterly Report of Dirui Healthcare (300396): Q3 revenue structure continues to be optimized, and reagent release is about to accelerate
Event: The company announced its results for the third quarter of 2023. 23Q1-Q3 achieved revenue of 1,049 million yuan (+30.7%), net profit of 234 million yuan (+20.4%), net profit of 2.29 million (+20.4%), and net profit of 2.29 per cent
Analysis
Price Target
No Data
